Recordati Acquires Sanofi’s Rare Disease Drug Enjaymo in $825M Deal

Acquisition Details:
Recordati has agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi for $825 million upfront, with additional milestone payments of up to $250 million contingent on sales performance.

Enjaymo Overview:
Enjaymo is a humanized monoclonal antibody approved for treating hemolysis in adults with cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

Regulatory Approvals:
Enjaymo has received approvals from the US FDA, European Commission, and the Japanese Ministry of Health, Labour and Welfare in 2022.

Revenue Projections:
Enjaymo generated approximately €100 million ($110 million) in revenue over the last 12 months as of August 2024 and is projected to generate more than €150 million in financial year 2025, with peak sales potentially reaching €250-300 million.

Strategic Impact:
The acquisition enhances Recordati’s rare diseases franchise and addresses a critical unmet medical need for patients with CAD.

Transaction Timeline:
The deal is expected to close by the end of 2024, pending regulatory approvals.